サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1800914

嚢胞性線維症治療市場レポート：薬剤クラス別、薬剤分子タイプ別、投与経路別、エンドユーザー別、地域別、2025年～2033年

Cystic Fibrosis Therapeutics Market Report by Drug Class, Drug Molecule Type, Route of Administration, End-User, and Region 2025-2033

出版日
発行
IMARC
ページ情報
英文 118 Pages
納期
2～3営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=148.30円
嚢胞性線維症治療市場レポート：薬剤クラス別、薬剤分子タイプ別、投与経路別、エンドユーザー別、地域別、2025年～2033年
出版日: 2025年08月01日
発行: IMARC
ページ情報: 英文 118 Pages
納期: 2～3営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の嚢胞性線維症治療の市場規模は2024年に78億米ドルに達しました。今後、IMARC Groupは、市場は2033年までに155億米ドルに達し、2025年から2033年にかけて7.55%の成長率（CAGR）を示すと予測しています。嚢胞性線維症の有病率の上昇、遺伝的要因に基づく個別化治療アプローチに対する個人の嗜好の高まり、遺伝子治療における最近の進歩の広範な利用は、市場成長を推進する主な要因の一部です。

嚢胞性線維症治療は、呼吸器系や消化器系に影響を及ぼす遺伝性疾患の症状管理を可能にします。CFTRモジュレーターや遺伝子治療を含む様々な薬剤が含まれ、オーダーメイドの治療オプションを提供します。CFTRタンパク質の機能を強化することにより、CFの原因となる根本的な遺伝子異常を改善します。症状を改善し、病気の進行を遅らせることで、生活の質の向上に貢献します。肺機能を強化することで、CF患者の呼吸を楽にし、呼吸器症状を軽減することができます。

遺伝的要因に基づく個別化治療に対する個人の嗜好の高まりが、市場の成長を強化しています。これとは別に、各国の行政当局がCFの研究や治療開発のための政策や資金を導入しており、市場の見通しを良好なものにしています。さらに、希少疾病用医薬品の開発に対する規制上の優遇措置の継続的な増加が、製薬会社のCF治療薬への投資を促しています。さらに、製薬会社、研究開発機関、ヘルスケアプロバイダー間の協力関係の高まりは、新たな治療法の開発を加速させています。さらに、ウェアラブルデバイスや遠隔医療などの技術の普及により、患者のモニタリングや治療の提供が強化されています。

嚢胞性線維症治療市場動向と促進要因：

CFTRモジュレーターの進歩

CFTR調節薬の開発と継続的な改良は、市場成長に寄与する主要因の一つです。これらの医薬品は、CF患者における濃い粘液産生とそれに続く健康合併症の原因である欠陥CFTRタンパク質を直接標的とします。これとは別に、製薬会社は、より高い有効性と幅広い適用性を提供する新世代のCFTRモジュレーターを導入するための研究開発活動に継続的に投資しています。これらの進歩は、より包括的な解決策を提供し、患者の全体的な健康を改善します。また、特定のCF患者集団における粘液クリアランスの改善、呼吸器症状の軽減、肺機能の向上もサポートしています。

遺伝子ベースの治療法の開発

遺伝子ベースの治療法の開発も、市場開拓を促進する大きな要因です。これらの革新的な治療は、CFTR遺伝子の機能不全コピーを罹患細胞に導入することにより、CFの根本原因に対処し、CFの治癒や長期管理を容易にします。さらに、KaftrioやTrikaftaのような遺伝子ベースの治療がCFの症状を治療するために承認されるなど、遺伝子治療における最近の進歩の利用が増加していることも、良好な市場見通しをもたらしています。これとは別に、遺伝子ベースの治療法の進化が市場の成長を強化しています。これらの治療法は、より効果的で的を絞った治療を提供し、治療の選択肢を広げ、潜在的な治療法の研究を促進するのに役立っています。

有病率の増加と早期診断

いくつかの要因により、特にミレニアル世代の間でCFの有病率が上昇していることが、治療薬に対する需要を押し上げています。これに伴い、診断能力の向上が市場の見通しを明るいものにしています。さらに、ヘルスケアシステムは、新生児スクリーニングプログラムや遺伝子検査を通じて、CF症例の特定に習熟しつつあります。これとは別に、早期診断により若年齢での治療開始が可能となり、疾患の進行に大きな影響を与え、長期的な転帰を改善することができます。さらに、遺伝子検査や新生児スクリーニングプログラムの進歩により、乳幼児におけるCFの診断がより迅速かつ確実に行われるようになってきています。

目次

第1章 序文

第2章 調査範囲と調査手法

  • 調査の目的
  • ステークホルダー
  • データソース
    • 一次情報
    • 二次情報
  • 市場推定
    • ボトムアップアプローチ
    • トップダウンアプローチ
  • 調査手法

第3章 エグゼクティブサマリー

第4章 イントロダクション

第5章 世界の嚢胞性線維症治療市場

  • 市場概要
  • 市場実績
  • COVID-19の影響
  • 市場予測

第6章 市場内訳：薬剤クラス別

  • 膵臓酵素サプリメント
  • 粘液溶解薬
  • 気管支拡張薬
  • CFTRモジュレーター
  • 抗生物質
  • その他

第7章 市場内訳：薬物分子タイプ別

  • 低分子医薬品
  • 生物学的製剤

第8章 市場内訳：投与経路別

  • 経口薬
  • 吸入薬

第9章 市場内訳：エンドユーザー別

  • 病院
  • クリニック
  • その他

第10章 市場内訳：地域別

  • 北米
    • 米国
    • カナダ
  • アジア太平洋地域
    • 中国
    • 日本
    • インド
    • 韓国
    • オーストラリア
    • インドネシア
    • その他
  • 欧州
    • ドイツ
    • フランス
    • 英国
    • イタリア
    • スペイン
    • ロシア
    • その他
  • ラテンアメリカ
    • ブラジル
    • メキシコ
    • その他
  • 中東・アフリカ

第11章 SWOT分析

第12章 バリューチェーン分析

第13章 ポーターのファイブフォース分析

第14章 価格分析

第15章 競合情勢

  • 市場構造
  • 主要企業
  • 主要企業のプロファイル
    • Abbvie Inc.
    • Alaxia
    • Alcresta Therapeutics Inc.
    • Allergan
    • AstraZeneca
    • F. Hoffmann-La Roche Ltd
    • Gilead Sciences Inc.
    • Merck & Co., Inc.
    • Novartis AG
    • Teva Pharmaceutical Industries Ltd.
    • Vertex Pharmaceuticals Inc.
図表

List of Figures

  • Figure 1: Global: Cystic Fibrosis Therapeutics Market: Major Drivers and Challenges
  • Figure 2: Global: Cystic Fibrosis Therapeutics Market: Sales Value (in Billion USD), 2019-2024
  • Figure 3: Global: Cystic Fibrosis Therapeutics Market: Breakup by Drug Class (in %), 2024
  • Figure 4: Global: Cystic Fibrosis Therapeutics Market: Breakup by Drug Molecule Type (in %), 2024
  • Figure 5: Global: Cystic Fibrosis Therapeutics Market: Breakup by Route of Administration (in %), 2024
  • Figure 6: Global: Cystic Fibrosis Therapeutics Market: Breakup by End-User (in %), 2024
  • Figure 7: Global: Cystic Fibrosis Therapeutics Market: Breakup by Region (in %), 2024
  • Figure 8: Global: Cystic Fibrosis Therapeutics Market Forecast: Sales Value (in Billion USD), 2025-2033
  • Figure 9: Global: Cystic Fibrosis Therapeutics (Pancreatic Enzyme Supplements) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 10: Global: Cystic Fibrosis Therapeutics (Pancreatic Enzyme Supplements) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 11: Global: Cystic Fibrosis Therapeutics (Mucolytics) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 12: Global: Cystic Fibrosis Therapeutics (Mucolytics) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 13: Global: Cystic Fibrosis Therapeutics (Bronchodilators) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 14: Global: Cystic Fibrosis Therapeutics (Bronchodilators) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 15: Global: Cystic Fibrosis Therapeutics (CFTR Modulators) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 16: Global: Cystic Fibrosis Therapeutics (CFTR Modulators) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 17: Global: Cystic Fibrosis Therapeutics (Antibiotics) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 18: Global: Cystic Fibrosis Therapeutics (Antibiotics) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 19: Global: Cystic Fibrosis Therapeutics (Others) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 20: Global: Cystic Fibrosis Therapeutics (Others) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 21: Global: Cystic Fibrosis Therapeutics (Small Molecule Drugs) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 22: Global: Cystic Fibrosis Therapeutics (Small Molecule Drugs) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 23: Global: Cystic Fibrosis Therapeutics (Biologics) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 24: Global: Cystic Fibrosis Therapeutics (Biologics) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 25: Global: Cystic Fibrosis Therapeutics (Oral Drugs) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 26: Global: Cystic Fibrosis Therapeutics (Oral Drugs) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 27: Global: Cystic Fibrosis Therapeutics (Inhaled Drugs) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 28: Global: Cystic Fibrosis Therapeutics (Inhaled Drugs) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 29: Global: Cystic Fibrosis Therapeutics (Hospitals) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 30: Global: Cystic Fibrosis Therapeutics (Hospitals) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 31: Global: Cystic Fibrosis Therapeutics (Clinics) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 32: Global: Cystic Fibrosis Therapeutics (Clinics) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 33: Global: Cystic Fibrosis Therapeutics (Others) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 34: Global: Cystic Fibrosis Therapeutics (Others) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 35: North America: Cystic Fibrosis Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 36: North America: Cystic Fibrosis Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 37: United States: Cystic Fibrosis Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 38: United States: Cystic Fibrosis Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 39: Canada: Cystic Fibrosis Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 40: Canada: Cystic Fibrosis Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 41: Asia Pacific: Cystic Fibrosis Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 42: Asia Pacific: Cystic Fibrosis Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 43: China: Cystic Fibrosis Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 44: China: Cystic Fibrosis Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 45: Japan: Cystic Fibrosis Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 46: Japan: Cystic Fibrosis Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 47: India: Cystic Fibrosis Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 48: India: Cystic Fibrosis Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 49: South Korea: Cystic Fibrosis Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 50: South Korea: Cystic Fibrosis Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 51: Australia: Cystic Fibrosis Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 52: Australia: Cystic Fibrosis Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 53: Indonesia: Cystic Fibrosis Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 54: Indonesia: Cystic Fibrosis Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 55: Others: Cystic Fibrosis Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 56: Others: Cystic Fibrosis Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 57: Europe: Cystic Fibrosis Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 58: Europe: Cystic Fibrosis Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 59: Germany: Cystic Fibrosis Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 60: Germany: Cystic Fibrosis Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 61: France: Cystic Fibrosis Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 62: France: Cystic Fibrosis Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 63: United Kingdom: Cystic Fibrosis Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 64: United Kingdom: Cystic Fibrosis Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 65: Italy: Cystic Fibrosis Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 66: Italy: Cystic Fibrosis Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 67: Spain: Cystic Fibrosis Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 68: Spain: Cystic Fibrosis Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 69: Russia: Cystic Fibrosis Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 70: Russia: Cystic Fibrosis Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 71: Others: Cystic Fibrosis Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 72: Others: Cystic Fibrosis Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 73: Latin America: Cystic Fibrosis Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 74: Latin America: Cystic Fibrosis Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 75: Brazil: Cystic Fibrosis Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 76: Brazil: Cystic Fibrosis Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 77: Mexico: Cystic Fibrosis Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 78: Mexico: Cystic Fibrosis Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 79: Others: Cystic Fibrosis Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 80: Others: Cystic Fibrosis Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 81: Middle East and Africa: Cystic Fibrosis Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 82: Middle East and Africa: Cystic Fibrosis Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 83: Global: Cystic Fibrosis Therapeutics Industry: SWOT Analysis
  • Figure 84: Global: Cystic Fibrosis Therapeutics Industry: Value Chain Analysis
  • Figure 85: Global: Cystic Fibrosis Therapeutics Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Cystic Fibrosis Therapeutics Market: Key Industry Highlights, 2024 and 2033
  • Table 2: Global: Cystic Fibrosis Therapeutics Market Forecast: Breakup by Drug Class (in Million USD), 2025-2033
  • Table 3: Global: Cystic Fibrosis Therapeutics Market Forecast: Breakup by Drug Molecule Type (in Million USD), 2025-2033
  • Table 4: Global: Cystic Fibrosis Therapeutics Market Forecast: Breakup by Route of Administration (in Million USD), 2025-2033
  • Table 5: Global: Cystic Fibrosis Therapeutics Market Forecast: Breakup by End-User (in Million USD), 2025-2033
  • Table 6: Global: Cystic Fibrosis Therapeutics Market Forecast: Breakup by Region (in Million USD), 2025-2033
  • Table 7: Global: Cystic Fibrosis Therapeutics Market Structure
  • Table 8: Global: Cystic Fibrosis Therapeutics Market: Key Players
目次
Product Code: SR112025A2117

The global cystic fibrosis therapeutics market size reached USD 7.8 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 15.5 Billion by 2033, exhibiting a growth rate (CAGR) of 7.55% during 2025-2033. The rising prevalence of cystic fibrosis, increasing preferences of individuals for personalized treatment approaches based on genetic factors, and the widespread utilization of recent advancements in gene therapy are some of the major factors propelling the market growth.

Cystic fibrosis therapeutics enables management of the symptoms of a genetic disease affecting the respiratory and digestive systems. It encompasses a range of drugs, including CFTR modulators and gene therapy, offering tailored treatment options. It helps correct the underlying genetic defect responsible for CF by enhancing the function of the CFTR protein. It contributes to a better quality of life by managing symptoms and slowing disease progression. It can enhance lung function, helping individuals with CF breathe more easily and reducing respiratory symptoms.

Rising preferences of individuals for personalized treatment approaches based on genetic factors is strengthening the growth of the market. Apart from this, governing authorities of various countries are introducing policies and funding for CF research and treatment development, which is offering a favorable market outlook. Additionally, a continuous rise in regulatory incentives for orphan drug development is encouraging pharmaceutical companies to invest in CF therapeutics. Moreover, the rising collaborative efforts between pharmaceutical companies, research institutions, and healthcare providers are accelerating the development of new therapies. Furthermore, the widespread use of technology, such as wearable devices and telemedicine, is enhancing patient monitoring and treatment delivery.

Cystic Fibrosis Therapeutics Market Trends/Drivers:

Advancements in CFTR modulators

The development and continued improvement of CFTR modulator drugs represent one of the primary factors contributing to the market growth. These medications directly target the defective CFTR protein, which is responsible for the thick mucus production and subsequent health complications in individuals with CF. Apart from this, pharmaceutical companies are continuously investing in research and development (R&D) activities to introduce new generations of CFTR modulators that offer greater effectiveness and broader applicability. These advancements provide more comprehensive solutions and improve the overall well-being of individuals. They also support improved mucus clearance, reduced respiratory symptoms, and enhanced lung function in specific CF patient populations.

Development of gene-based therapies

The development of gene-based therapies is another major factor facilitating the market growth. These innovative treatments help address the root cause of CF by introducing functional copies of the defective CFTR gene into affected cells and facilitating a cure or long-term management of CF. Additionally, the rising utilization of recent advancements in gene therapy, such as the approval of gene-based treatments like Kaftrio and Trikafta for treating CF symptoms is offering a favorable market outlook. Apart from this, the evolution of gene-based therapies is strengthening the growth of the market. These therapies aid in providing more effective and targeted treatments, expanding treatment options, and fostering research into potential curative approaches.

Increasing prevalence and early diagnosis

The rising prevalence of CF, especially among the millennial population due to several factors, is driving the demand for therapeutics. Along with this, improved diagnostic capabilities are creating a positive market outlook. Additionally, healthcare systems are becoming more adept at identifying CF cases through newborn screening programs and genetic testing. Apart from this, early diagnosis allows for the initiation of treatment at a younger age, which can significantly impact disease progression and improve long-term outcomes. Furthermore, ongoing advancements in genetic testing and newborn screening programs are allowing for quicker and more reliable diagnosis of CF in infants and young children.

Cystic Fibrosis Therapeutics Industry Segmentation:

Breakup by Drug Class:

  • Pancreatic Enzyme Supplements
  • Mucolytics
  • Bronchodilators
  • CFTR Modulators
  • Antibiotics
  • Others

CFTR modulators hold the largest market share

Breakup by Drug Molecule Type:

  • Small Molecule Drugs
  • Biologics

Small molecule drugs account for the majority of the market share

Breakup by Route of Administration:

  • Oral Drugs
  • Inhaled Drugs

Oral drugs dominate the market

Breakup by End-User:

  • Hospitals
  • Clinics
  • Others

Hospitals dominate the market

Breakup by Region:

  • North America
    • United States
    • Canada
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Others
  • Europe
    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
    • Russia
    • Others
  • Latin America
    • Brazil
    • Mexico
    • Others
  • Middle East and Africa

Europe leads the market, accounting for the largest cystic fibrosis therapeutics market share

The market research report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, Europe accounted for the largest market share since the region has a well-developed healthcare infrastructure with widespread access to medical facilities and specialized CF centers. Additionally, Europe has a relatively high prevalence of CF. This increased prevalence drives research and development (R&D) efforts as well as market demand for CF therapeutics. Apart from this, Europe is home to some of the largest pharmaceutical companies in the world. These companies invest heavily in CF therapeutics, leading to the development of innovative treatments. Furthermore, the European Medicines Agency (EMA) provides a clear regulatory pathway for the approval of CF drugs. Moreover, many European governments allocate substantial funding to support CF research and treatment. This funding accelerates the development of new therapies and promotes market growth.

Competitive Landscape:

Companies are investing heavily in research and development (R&D) activities to discover new treatments and medications that target the underlying causes of cystic fibrosis. Additionally, they are working on therapies tailored to specific genetic mutations associated with cystic fibrosis. This ensures a more effective and targeted approach to treatment. Apart from this, many companies are forming partnerships with academic institutions, research organizations, and other pharma companies to accelerate drug development and bring new therapies to market more quickly. Furthermore, they are continuously conducting and investing in phase I, II, and III clinical trials to test the efficacy and safety of new cystic fibrosis therapies.

The market research report has provided a comprehensive analysis of the competitive landscape. Detailed profiles of all major companies have also been provided. Some of the key players in the market include:

  • AbbVie Inc.
  • Alaxia
  • Alcresta Therapeutics Inc.
  • Allergan
  • AstraZeneca
  • F. Hoffmann-La Roche Ltd.
  • Gilead Sciences Inc.
  • Merck & Co. Inc.
  • Novartis AG
  • Teva Pharmaceutical Industries Ltd.
  • Vertex Pharmaceuticals Inc.

Key Questions Answered in This Report:

  • How has the global cystic fibrosis therapeutics market performed so far, and how will it perform in the coming years?
  • What are the drivers, restraints, and opportunities in the global cystic fibrosis therapeutics market?
  • What is the impact of each driver, restraint, and opportunity on the global cystic fibrosis therapeutics market?
  • What are the key regional markets?
  • Which countries represent the most attractive cystic fibrosis therapeutics market?
  • What is the breakup of the market based on the drug class?
  • Which is the most attractive drug class in the cystic fibrosis therapeutics market?
  • What is the breakup of the market based on the drug molecule type?
  • Which is the most attractive drug molecule type in the cystic fibrosis therapeutics market?
  • What is the breakup of the market based on the route of administration?
  • Which is the most attractive route of administration in the cystic fibrosis therapeutics market?
  • What is the breakup of the market based on the end-user?
  • Which is the most attractive end-user in the cystic fibrosis therapeutics market?
  • What is the competitive structure of the global cystic fibrosis therapeutics market?
  • Who are the key players/companies in the global cystic fibrosis therapeutics market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Cystic Fibrosis Therapeutics Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Drug Class

  • 6.1 Pancreatic Enzyme Supplements
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Mucolytics
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Bronchodilators
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 CFTR Modulators
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast
  • 6.5 Antibiotics
    • 6.5.1 Market Trends
    • 6.5.2 Market Forecast
  • 6.6 Others
    • 6.6.1 Market Trends
    • 6.6.2 Market Forecast

7 Market Breakup by Drug Molecule Type

  • 7.1 Small Molecule Drugs
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Biologics
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast

8 Market Breakup by Route of Administration

  • 8.1 Oral Drugs
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Inhaled Drugs
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast

9 Market Breakup by End-User

  • 9.1 Hospitals
    • 9.1.1 Market Trends
    • 9.1.2 Market Forecast
  • 9.2 Clinics
    • 9.2.1 Market Trends
    • 9.2.2 Market Forecast
  • 9.3 Others
    • 9.3.1 Market Trends
    • 9.3.2 Market Forecast

10 Market Breakup by Region

  • 10.1 North America
    • 10.1.1 United States
      • 10.1.1.1 Market Trends
      • 10.1.1.2 Market Forecast
    • 10.1.2 Canada
      • 10.1.2.1 Market Trends
      • 10.1.2.2 Market Forecast
  • 10.2 Asia Pacific
    • 10.2.1 China
      • 10.2.1.1 Market Trends
      • 10.2.1.2 Market Forecast
    • 10.2.2 Japan
      • 10.2.2.1 Market Trends
      • 10.2.2.2 Market Forecast
    • 10.2.3 India
      • 10.2.3.1 Market Trends
      • 10.2.3.2 Market Forecast
    • 10.2.4 South Korea
      • 10.2.4.1 Market Trends
      • 10.2.4.2 Market Forecast
    • 10.2.5 Australia
      • 10.2.5.1 Market Trends
      • 10.2.5.2 Market Forecast
    • 10.2.6 Indonesia
      • 10.2.6.1 Market Trends
      • 10.2.6.2 Market Forecast
    • 10.2.7 Others
      • 10.2.7.1 Market Trends
      • 10.2.7.2 Market Forecast
  • 10.3 Europe
    • 10.3.1 Germany
      • 10.3.1.1 Market Trends
      • 10.3.1.2 Market Forecast
    • 10.3.2 France
      • 10.3.2.1 Market Trends
      • 10.3.2.2 Market Forecast
    • 10.3.3 United Kingdom
      • 10.3.3.1 Market Trends
      • 10.3.3.2 Market Forecast
    • 10.3.4 Italy
      • 10.3.4.1 Market Trends
      • 10.3.4.2 Market Forecast
    • 10.3.5 Spain
      • 10.3.5.1 Market Trends
      • 10.3.5.2 Market Forecast
    • 10.3.6 Russia
      • 10.3.6.1 Market Trends
      • 10.3.6.2 Market Forecast
    • 10.3.7 Others
      • 10.3.7.1 Market Trends
      • 10.3.7.2 Market Forecast
  • 10.4 Latin America
    • 10.4.1 Brazil
      • 10.4.1.1 Market Trends
      • 10.4.1.2 Market Forecast
    • 10.4.2 Mexico
      • 10.4.2.1 Market Trends
      • 10.4.2.2 Market Forecast
    • 10.4.3 Others
      • 10.4.3.1 Market Trends
      • 10.4.3.2 Market Forecast
  • 10.5 Middle East and Africa
    • 10.5.1 Market Trends
    • 10.5.2 Market Breakup by Country
    • 10.5.3 Market Forecast

11 SWOT Analysis

  • 11.1 Overview
  • 11.2 Strengths
  • 11.3 Weaknesses
  • 11.4 Opportunities
  • 11.5 Threats

12 Value Chain Analysis

13 Porters Five Forces Analysis

  • 13.1 Overview
  • 13.2 Bargaining Power of Buyers
  • 13.3 Bargaining Power of Suppliers
  • 13.4 Degree of Competition
  • 13.5 Threat of New Entrants
  • 13.6 Threat of Substitutes

14 Price Analysis

15 Competitive Landscape

  • 15.1 Market Structure
  • 15.2 Key Players
  • 15.3 Profiles of Key Players
    • 15.3.1 Abbvie Inc.
      • 15.3.1.1 Company Overview
      • 15.3.1.2 Product Portfolio
      • 15.3.1.3 Financials
      • 15.3.1.4 SWOT Analysis
    • 15.3.2 Alaxia
      • 15.3.2.1 Company Overview
      • 15.3.2.2 Product Portfolio
    • 15.3.3 Alcresta Therapeutics Inc.
      • 15.3.3.1 Company Overview
      • 15.3.3.2 Product Portfolio
    • 15.3.4 Allergan
      • 15.3.4.1 Company Overview
      • 15.3.4.2 Product Portfolio
      • 15.3.4.3 Financials
      • 15.3.4.4 SWOT Analysis
    • 15.3.5 AstraZeneca
      • 15.3.5.1 Company Overview
      • 15.3.5.2 Product Portfolio
      • 15.3.5.3 Financials
      • 15.3.5.4 SWOT Analysis
    • 15.3.6 F. Hoffmann-La Roche Ltd
      • 15.3.6.1 Company Overview
      • 15.3.6.2 Product Portfolio
    • 15.3.7 Gilead Sciences Inc.
      • 15.3.7.1 Company Overview
      • 15.3.7.2 Product Portfolio
      • 15.3.7.3 Financials
      • 15.3.7.4 SWOT Analysis
    • 15.3.8 Merck & Co., Inc.
      • 15.3.8.1 Company Overview
      • 15.3.8.2 Product Portfolio
      • 15.3.8.3 Financials
      • 15.3.8.4 SWOT Analysis
    • 15.3.9 Novartis AG
      • 15.3.9.1 Company Overview
      • 15.3.9.2 Product Portfolio
      • 15.3.9.3 Financials
      • 15.3.9.4 SWOT Analysis
    • 15.3.10 Teva Pharmaceutical Industries Ltd.
      • 15.3.10.1 Company Overview
      • 15.3.10.2 Product Portfolio
      • 15.3.10.3 Financials
      • 15.3.10.4 SWOT Analysis
    • 15.3.11 Vertex Pharmaceuticals Inc.
      • 15.3.11.1 Company Overview
      • 15.3.11.2 Product Portfolio
      • 15.3.11.3 Financials
      • 15.3.11.4 SWOT Analysis